Praxis Precision Medicines (PRAX) Cash from Financing Activities (2019 - 2026)

Praxis Precision Medicines has reported Cash from Financing Activities for 8 years, with the latest figure at $609.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 1022.98% year-over-year to $609.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 225.87% YoY), and the FY2025 full-year result was $702.2 million, up 36.52% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $609.4 million, down from $612.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $612.5 million in Q4 2025, with the low at $504000.0 in Q2 2022.
• Average Cash from Financing Activities over 5 years is $120.5 million, with a median of $23.3 million recorded in 2023.
• Year-over-year, Cash from Financing Activities tumbled 99.49% in 2022 and surged 13724.4% in 2023.
• Tracing PRAX's Cash from Financing Activities over 5 years: stood at $5.4 million in 2022, then decreased by 23.41% to $4.1 million in 2023, then surged by 2657.32% to $113.8 million in 2024, then soared by 438.4% to $612.5 million in 2025, then retreated by 0.5% to $609.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $609.4 million (Q1 2026), $612.5 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.

Peer Comparison